Sort   by:  
 Page size 
TranscriptomicsTranscription profiling of mouse transition from normal intestine to adenoma in the apc(min/+) mouse
Transcriptional Profiling of the Transition from Normal Intestine to Adenoma in the APC(Min/+) Mouse. Tissue was from male 91-days old APC(Min/+) mouse (an animal model for human colon cancer). RNA was purified using Trizol and labeled for hybridization to high density oligonucleotide Affymetrix MG_...
ORGANISM(S): Mus musculus 
2008-06-15 | E-GEOD-784 | biostudies-arrayexpress
TranscriptomicsExpression data from mouse intestine: C57Bl/6 MTHFR+/- vs BALB/c MTHFR+/-
Previous studies in our laboratory have shown that low folate diet (control diet with 2mg folate/kg, low folate diet with 0.3mg folate/kg) can induce intestinal tumors in BALB/c mice. In addition, we reported that C57Bl/6J mice did not form tumors under the same conditions. We used microarrays to id...
ORGANISM(S): Mus musculus 
2013-04-09 | E-GEOD-34010 | biostudies-arrayexpress
TranscriptomicsExpression data from mouse intestine: BALB/c MTHFR+/+ on control diet vs BALB/c MTHFR+/- on folate deficient diet
Previous studies in our laboratory have shown that low folate diet (control diet with 2mg folate/kg, low folate diet with 0.3mg folate/kg) can induce intestinal tumors in BALB/c mice. We used microarrays to compare MTHFR+/+ BALB/c mice fed control diet and MTHFR+/- BALB/c mice fed low folate diet. ...
ORGANISM(S): Mus musculus 
2013-12-03 | E-GEOD-34011 | biostudies-arrayexpress
TranscriptomicsRNA at 92 M-BM-0C: the non-coding transcriptome of the hyperthermophilic archaeon Pyrococcus abyssi.
The non-coding transcriptome of the hyperthermophilic archaeon Pyrococcus abyssi is investigated using the RNA-seq technology. A dedicated computational pipeline analyzes RNA-seq reads and prior genome annotation to identify small RNAs, untranslated regions of mRNAs, and cis-encoded antisense transc...
ORGANISM(S): Pyrococcus abyssi 
2014-05-31 | E-GEOD-58131 | biostudies-arrayexpress
UnknownLong-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.
Not available
S-EPMC7649610 | biostudies-literature
UnknownGWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.
Not available
S-EPMC5363591 | biostudies-literature
UnknownConstitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.
Not available
S-EPMC5445615 | biostudies-literature
UnknownAssessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
Not available
S-EPMC5568360 | biostudies-literature
UnknownPredicting 90-day survival of patients with COVID-19: Survival of Severely Ill COVID (SOSIC) scores.
Not available
S-EPMC8665857 | biostudies-literature
UnknownMutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
Not available
S-EPMC4301157 | biostudies-literature
Sort   by:  
 Page size